Please login to the form below

Not currently logged in
Email:
Password:

Sucampo moves on EU market

US pharmaceutical company, Sucampo, has launched a bid to compete in the European marketplace by filing a marketing authorisation application in Switzerland for its drug, Amitiza
US pharmaceutical company, Sucampo, has launched a bid to compete in the European marketplace by filing a marketing authorisation application (MAA) in Switzerland for its drug, Amitiza.

It has been developed for the treatment of chronic idiopathic constipation and is already available in the US. Sucampo hopes that it will soon be approved for use in Switzerland and is keen to build on what it has referred to as ëthe drug's success in the US' to extend its operations into the EU.

"We are systematically developing additional marketing opportunities outside the US," said Dr Ryuji Ueno, founder, chairman and CEO of Sucampo.

"This application is a continuation of these efforts as well as an ongoing expansion of our European operations."

The MAA has been submitted to SwissMedic, the regulatory body for medical products in Switzerland. The US Food and Drug Administration (FDA) first approved the drug for the treatment of chronic idiopathic constipation in adults in April 2006 and subsequently extended its uses for women suffering from irritable bowel syndrome (IBS) with constipation.

Nine other EU countries are currently reviewing MAAs for Amitiza, which were filed by Sucampo. Excluding the drug's marketing licence in the US, the company retains all commercial rights for the product in the whole of Europe and the rest of the world.

9th June 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics